NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free HRMY Stock Alerts $29.03 -0.28 (-0.96%) (As of 05/17/2024 06:55 PM ET) Add Compare Share Share Today's Range$28.87▼$29.5650-Day Range$28.85▼$33.6552-Week Range$18.61▼$39.26Volume334,500 shsAverage Volume392,522 shsMarket Capitalization$1.65 billionP/E Ratio12.57Dividend YieldN/APrice Target$40.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside39.9% Upside$40.63 Price TargetShort InterestBearish16.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.12Based on 2 Articles This WeekInsider TradingSelling Shares$389,536 Sold Last QuarterProj. Earnings Growth52.96%From $2.53 to $3.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.03 out of 5 starsMedical Sector172nd out of 914 stocksPharmaceutical Preparations Industry68th out of 427 stocks 3.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.05% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 4.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 2.3 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,536.00 in company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 52.96% in the coming year, from $2.53 to $3.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 12.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 12.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 151.76.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesMay 17 at 1:56 AM | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 6, 2024 | msn.comHarmony Biosciences Expands into Rare Epilepsy Market with Epygenix Therapeutics AcquisitionMay 4, 2024 | finance.yahoo.comResults: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsMay 3, 2024 | finance.yahoo.comHarmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats ExpectationsMay 2, 2024 | markets.businessinsider.comLooking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid ChoiceMay 2, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Q1 2024 Earnings Call Transcript Highlights: Strong ...May 1, 2024 | msn.comEasterly Government Properties, Inc. (NYSE:DEA) Q1 2024 Earnings Call TranscriptApril 30, 2024 | msn.comRapidly Growing Harmony Biosciences Sees 30% Increase in Net Revenue, Boosts Growth Strategy With Rare Epilepsy Franchise AcquisitionApril 30, 2024 | bizjournals.comHarmony Biosciences shares soar on acquisition of New Jersey epilepsy drug developerApril 30, 2024 | fool.comHarmony Biosciences (HRMY) Q1 2024 Earnings Call TranscriptApril 30, 2024 | seekingalpha.comHarmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)April 30, 2024 | marketwatch.comHarmony Biosciences Buys Epygenix Therapeutics For Initial $35 MillionApril 30, 2024 | marketwatch.comHarmony Biosciences Shares Rise After Earnings, AcquisitionApril 30, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)April 30, 2024 | markets.businessinsider.comKey Takeaways From Harmony Biosciences Analyst RatingsApril 30, 2024 | msn.comHRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.comHarmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024April 30, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 30, 2024 | globenewswire.comHarmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare EpilepsyApril 30, 2024 | prnewswire.comHarmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsApril 29, 2024 | markets.businessinsider.comHarmony Biosciences earnings: here's what Wall Street expectsApril 29, 2024 | msn.comHarmony Biosciences Q1 2024 Earnings PreviewApril 22, 2024 | msn.comHarmony Biosciences to Unveil Q1 2024 Financial ResultsApril 16, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024See More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/20/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees246Year FoundedN/APrice Target and Rating Average Stock Price Target$40.63 High Stock Price Target$59.00 Low Stock Price Target$27.00 Potential Upside/Downside+39.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.31 Trailing P/E Ratio12.57 Forward P/E Ratio11.47 P/E Growth0.47Net Income$128.85 million Net Margins22.30% Pretax Margin30.35% Return on Equity28.26% Return on Assets17.23% Debt Debt-to-Equity Ratio0.34 Current Ratio3.11 Quick Ratio3.07 Sales & Book Value Annual Sales$582.02 million Price / Sales2.83 Cash Flow$2.61 per share Price / Cash Flow11.13 Book Value$9.08 per share Price / Book3.20Miscellaneous Outstanding Shares56,790,000Free Float39,300,000Market Cap$1.65 billion OptionableOptionable Beta0.75 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $185.67kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $1.26MMr. Sandip S. Kapadia CPA (Age 54)M.B.A., Executive VP, Chief Administrative Officer & CFO Comp: $813.52kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRVice Presidet of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMs. Kelli WrightSenior Manager of Patient Advocacy & Harmony BiosciencesMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRStructure TherapeuticsNASDAQ:GPCRProtagonist TherapeuticsNASDAQ:PTGXEdgewise TherapeuticsNASDAQ:EWTXKura OncologyNASDAQ:KURAView All CompetitorsInsiders & InstitutionsComerica BankSold 1,785 shares on 5/17/2024Ownership: 0.024%Hancock Whitney CorpBought 10,547 shares on 5/17/2024Ownership: 0.019%Jacobs Levy Equity Management Inc.Sold 1,408 shares on 5/16/2024Ownership: 0.418%Janus Henderson Group PLCBought 168,434 shares on 5/16/2024Ownership: 0.326%California State Teachers Retirement SystemSold 2,487 shares on 5/16/2024Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price target for 2024? 8 Wall Street analysts have issued 1 year price targets for Harmony Biosciences' shares. Their HRMY share price targets range from $27.00 to $59.00. On average, they anticipate the company's share price to reach $40.63 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2024? Harmony Biosciences' stock was trading at $32.30 at the beginning of the year. Since then, HRMY shares have decreased by 10.1% and is now trading at $29.03. View the best growth stocks for 2024 here. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our HRMY earnings forecast. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its earnings results on Tuesday, April, 30th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.07. The firm earned $154.62 million during the quarter, compared to analyst estimates of $154.10 million. Harmony Biosciences had a trailing twelve-month return on equity of 28.26% and a net margin of 22.30%. The firm's revenue for the quarter was up 29.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap 600 GARP ETF (GRPZ), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco S&P SmallCap Health Care ETF (PSCH).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Harmony Biosciences issued on next quarter's earnings? Harmony Biosciences updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $710.2 million. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.39%), LSV Asset Management (0.59%), Jacobs Levy Equity Management Inc. (0.42%), Capital Management Corp VA (0.37%), Principal Financial Group Inc. (0.34%) and Janus Henderson Group PLC (0.33%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HRMY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward PressBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
